Evidence map›Paper›PMID 42589387›Full record

ReviewInternational journal of molecular sciences2026

Tetranectin: Molecular Mechanisms, Biological Functions and Clinical Implications.

Sarfraz Ahmed, Sana Iram, Amar Akash, Kwonyoung Kim, Jihoe Kim

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarfraz AhmedDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Sana IramDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Amar AkashDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Kwonyoung KimDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Jihoe KimDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.ORCID 0000-0002-1905-1452

Funding

Ministry of Education 2020R1A6A1A03044512 and RS-2025-02215727
6 · The paper itself

Abstract

Tetranectin (TN), also known as C-type lectin domain family 3 member B (CLEC3B), is a secreted glycoprotein originally identified through its high-affinity interaction with plasminogen. Although initially linked to fibrinolysis, TN is now increasingly recognized as an extracellular regulator associated with matrix remodeling, bone development, tissue repair, and disease-related proteolytic processes. Dysregulated TN expression has been reported in a broad range of pathological conditions, including cancer, cardiovascular disease, inflammatory disorders, and neurodegenerative states. In this review, we summarize current knowledge of TN with emphasis on its molecular architecture, ligand-binding properties, trimeric organization, and regulatory mechanisms. We further discuss its context-dependent biological functions, with particular attention to how tissue-specific and compartment-specific TN patterns may influence disease progression and clinical interpretation, especially in oncology. In addition, we evaluate the evidence supporting TN as a diagnostic and prognostic biomarker and consider its emerging therapeutic relevance. Finally, we outline the major challenges that currently limit clinical translation and highlight key directions for future investigation.

Indexed as

Lectins, C-TypeAnimalsBiomarkersHumansNeoplasmsBiomarkersLectins, C-TypetetranectinbiomarkercancerCLEC3Bextracellular matrixplasminogenproteolysistetranectin

Identifiers

PMID42589387
PMCPMC13466976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.